A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

Clinical trial NCT06130553 · RECRUITING

Trial details

NCT number: NCT06130553
Sponsor: AstraZeneca
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumors That Are MTAP Deficient

Start date: 2024-01-18
Primary completion: 2028-12-04
Enrollment: 334

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.